Veea Inc. (NASDAQ:VEEA), a provider of AI-powered, cybersecure edge infrastructure, and NovaGen Group B.V., a personalized regenerative medicine and longevity company, today announced they have signed a term sheet to combine and are targeting execution of a definitive business combination agreement within the coming weeks. In connection with the business combination, the parties have also announced an agreement to launch NovaGen Health Networks: a connected health platform integrating Veea’s edge computing, connectivity and cybersecurity capabilities with NovaGen’s cellular reprogramming science and clinical services. Initial deployments will begin at NovaGen clinics and partner hospitals in Q4 2026.

The platform, built on VeeaONE, connects health records, wearable and sensor data, and biological measurements into a patient-controlled longitudinal health profile. Local computing supports agentic AI applications close to the patient, with patient-directed permissions governing access to personal data. Rollout begins with connected health services and will expand to clinician-supervised diagnostics and therapy pathways as clinical validation and applicable regulatory authorizations permit.

GeoNova Capital, as cornerstone investor, has signed a term sheet to provide an initial US$10 million investment in the combined company. Veea will continue to grow and serve its existing customers, partners and markets. Management believes that, based on its internal projections and an independent valuation prepared using such internal projections, the value of the combined company is approximately $750 million.

The business combination between Veea and NovaGen, as well as the investment by GeoNova Capital, remains subject to the negotiation and execution of definitive documentation and the satisfaction of certain conditions to closing by the parties.

The companies plan to roll out NovaGen Health Networks in two phases.

Phase 1 – Connecting People, Data and Care (Q4 2026)

NovaGen Health Networks will provide a private household health hub with a digital twin for every family member and a patient-controlled health records wallet, integrating health records, wearable telemetry and longitudinal biological measurements. Built on VeeaONE, the hub processes sensitive data locally and supports AI wellness companions, medication reminders, and patient-authorized provider sharing. Plans include personal cell banking and consented research participation, subject to applicable regulatory requirements.

Phase 2 – Clinician-Supervised Diagnostics and Therapy Pathways

As clinical validation and regulatory authorizations permit, the network will combine digital twins and medical records with cellular data from the small skin biopsy used to initiate the ARC Prometheus process. This biopsy provides a patient’s own fibroblasts for cellular reprogramming, rejuvenation, cell banking and potential future autologous therapies. Telomere length, DNA-methylation age and additional biomarkers will be assessed to support clinician evaluation of therapy candidates and treatment monitoring. Validated AI tools will support clinician-reviewed decisions and referrals to authorized treatment centers.